PTC Therapeutics, Inc. (PTCT) — 分析摘要
PTC Therapeutics, Inc.（PTCT）的市值为5.40十亿美元，最近一年的营收同比增长了+114.5%。净利润率为39.4%。当前市盈率为-140.7倍。
核心要点
- 营收同比变化+114.5%
- 净利润率39.4%
- 市盈率-140.7倍
与PHARMACEUTICAL PREPARATIONS板块的其他公司相比，PTCT的营收增长为+114.5%，市盈率为-140.7倍。
PTC Therapeutics, Inc. (PTCT)
前收盘价 2026-10-12 · 市场数据 POLYGON · 财务数据 SEC EDGAR
红旗与风险提示高风险信号
存在多项实质性红旗，在依赖任何估值输出前应先重点核查这些风险。
营收较上一期下降 41.7%。
净利润由上一期盈利转为亏损。
股东权益为负，可能意味着资产负债表承压。
营业利润率 (12.5%) 超过毛利率 (0.0%) — 请检查其他营业收入或数据分类问题
PTC Therapeutics Inc is a biopharmaceutical company that discovers, develops and commercializes clinically differentiated medicines that provide benefits to children and adults living with rare disorders. Its diversified therapeutic portfolio that includes several commercial products and product candidates in various stages of development, including discovery, research and clinical stages, focused on the development of new treatments for multiple therapeutic areas for rare diseases relating to neurology and metabolism. The company views its operations and manages its business in one operating segment: life science, which is focused on the discovery, development and commercialization of the company's clinically differentiated medicines that provide benefits to patients with rare disorders.
行业
PHARMACEUTICAL PREPARATIONS
员工人数
991
总部
WARREN, NJ
Exchange
XNAS
基于 4 年财务数据的系统性竞争优势评估
此评估基于历史财务数据的量化分析，不构成投资建议。护城河评级可能随行业和竞争环境变化。
首版展示近期 SEC Forms 3、4、5 备案活动。尚未解析单笔买入/卖出交易。
资本结构
现金流
免责声明：本站内容不构成投资建议。数据来源于SEC EDGAR和Polygon.io。过往业绩不代表未来表现。投资决策前请自行研究。